Androgen sensitivity in women.

Identification of psychometric and biological markers to assess androgen and serotonergic sensitivity in relation to sexual functioning in women.

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON25052

Enrollment

200

Registered

2010-12-15

Start date

2010-12-06

Completion date

Unknown

Last updated

2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Androgen sensitivity Serotonergic sensitivity Female sexual dysfunction Androgeen sensitiviteit Serotonine sensitiviteit Seksueel disfunctioneren bij vrouwen

Interventions

After giving written informed consent and meeting the in- and exclusion criteria these subjects are enrolled in the study. The subjects will visit the study site once. An urine drug screening and alco

2. Urine drug analysis, pregnancy test and alcohol breath test

3. Enrolment

4. Stroop task

5. Filling out questionnaires: SAQ, SFQ, SSEQ and SMQ

6. Hand scan measuring the digit ratio

7. Blood sample collected for determination of [CAG]n, genotype SERT and 5HT1a receptor and hormone spectrum.

Eligibility

Inclusion criteria

Inclusion criteria: 1. Provision of written informed consent; 2. Female 21-70 years of age; 3. Healthy according to normal results of medical history; 4. Subject must be heterosexually oriented; 5. BMI ≥ 18 and ≤ 30 kg/m2; 6. Dutch as first language,

Exclusion criteria

Exclusion criteria: 1. Subjects who have had hand surgery interfering with measurement of digit lengths; 2. Subjects with musculoskeletal conditions affecting the measurements of digit lengths; 3. Known conditions associated with abnormal prenatal androgen exposure, namely congenital adrenal hyperplasia and complete androgen insensitivity syndrome; 4. Positive drug test and/or positive alcohol test; 5. Subjects with dyslexia; 6. Subjects who are color-blind; 7. Positive urine pregnancy test; 8. Use of oral contraception containing anti-androgens (e.g. Diane 35; Minerva); 9. Use of oral contraception containing 50 µg estrogen or more; 10. Homosexual orientation.

Design outcomes

Primary

Measure	Time frame
1. [CAG]n (blood); 2. Calculated second to fourth digit ratio (handscan); 3. Pre-attentional bias for erotic stimuli (Stroop task); 4. Blood serum free testosterone levels.	—

Secondary

Measure	Time frame
1. Blood serum levels ADT-G, 3µ-diol-G, DHEA and DHEA(s); 2. Genotype SERT and 5HT1a receptor (blood); 3. Questionnaires: SAQ, SSEQ and SMQ.	—

Contacts

Public ContactSaskia Poels

Louis Armstrongweg 78

s.poels@emotionalbrain.nl+31 (0)36 5468346

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)